OncoMatch/Clinical Trials/NCT07754890
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
Is NCT07754890 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including golidocitinib and Chidamide for cutaneous t-cell lymphoma (ctcl).
Treatment: golidocitinib · Chidamide — This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma. The primary endpoint of the phase I study was to determine the recommended phase II dose (RP2D), while the primary endpoint of the phase II study was the objective response rate (ORR). Secondary endpoints included the complete response (CR) rate, progression-free survival (PFS), duration of response (DOR), overall survival (OS), and safety profile.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IB, IIA, IIB, III, IVA, IVB
measurable disease, with or without extracutaneous lesions, and clinical stage IB-IVB
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic therapy (total skin electron beam therapy, bexarotene, retinoids, interferon, extracorporeal photopheresis, methotrexate, chidamide)
Disease that has not responded to or has relapsed after at least one prior systemic therapy (including, but not limited to, total skin electron beam therapy, bexarotene, retinoids, interferon, extracorporeal photopheresis, methotrexate, or chidamide)
Lab requirements
Blood counts
ANC ≥1.5×10⁹/L, PLT ≥80×10⁹/L, HGB ≥90 g/L
Kidney function
eGFR > 60 mL/min/1.73m²
Liver function
ALT < 2.5 × ULN, TBil < 1.5 × ULN
Cardiac function
NYHA Class 1-2, LVEF ≥50%
Adequate bone marrow function: Absolute Neutrophil Count (ANC) ≥1.5×10⁹/L, Platelet count (PLT) ≥80×10⁹/L, Hemoglobin (HGB) ≥90 g/L. Adequate organ function: Cardiac function Class 1-2 (NYHA), Left Ventricular Ejection Fraction (LVEF) ≥50%, Alanine Aminotransferase (ALT) < 2.5 × Upper Limit of Normal (ULN), Total Bilirubin (TBil) < 1.5 × ULN, Oxygen Saturation (SpO₂) > 93% on Room Air, estimated Glomerular Filtration Rate (eGFR) based on serum creatinine (sCr) > 60 mL/min/1.73m².
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07754890 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
What disease stage is eligible?
Stage IB or IIA or IIB or III or IVA or IVB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages